Iovance Biotherapeutics, Inc. (IOVA) has a negative trailing P/E of -3.9, meaning the company is currently unprofitable on a trailing twelve-month (TTM) basis. The forward P/E of 45.5 based on analyst estimates suggests a return to profitability is expected. Trailing earnings yield is -25.79%, forward earnings yield 2.20%. PEG 0.36 (Peter Lynch undervalued ≤1.0).
Criteria proven by this page:
Overall SharesGrow Score: 50/100 with 3/7 criteria passed.
| Year | P/E (TTM) | PEG Ratio | P/B Ratio | P/S Ratio | Dividend Yield |
|---|---|---|---|---|---|
| 2016 | -7.3 | -0.13 | 2.30 | 0.00 | 12.87% |
| 2017 | -5.7 | -0.12 | 3.59 | 0.00 | - |
| 2018 | -7.0 | 0.70 | 1.85 | 0.00 | - |
| 2019 | -17.4 | -0.96 | 11.51 | 0.00 | - |
| 2020 | -24.7 | -0.98 | 9.77 | 0.00 | - |
| 2021 | -8.6 | -0.46 | 4.71 | 0.00 | - |
| 2022 | -2.6 | -0.22 | 2.04 | 0.00 | - |
| 2023 | -4.3 | 0.18 | 3.27 | 1,607.75 | - |
| 2024 | -5.8 | 0.18 | 3.02 | 13.07 | - |
| 2025 | -2.5 | 0.17 | 1.40 | 3.70 | - |
| Year | EPS (Diluted) | Revenue | Net Income | Net Margin |
|---|---|---|---|---|
| 2016 | $-0.96 | $0.00 | $-52.89M | - |
| 2017 | $-1.41 | $0.00 | $-92.06M | - |
| 2018 | $-1.27 | $0.00 | $-123.58M | - |
| 2019 | $-1.50 | $0.00 | $-197.56M | - |
| 2020 | $-1.86 | $0.00 | $-259.58M | - |
| 2021 | $-2.14 | $0.00 | $-342.25M | - |
| 2022 | $-2.45 | $0.00 | $-395.89M | - |
| 2023 | $-1.89 | $1.19M | $-444.04M | -37345.4% |
| 2024 | $-1.28 | $164.07M | $-372.18M | -226.8% |
| 2025 | $-1.09 | $263.5M | $-390.98M | -148.4% |
| Year | EPS (Avg) | EPS Range | Revenue (Avg) | Revenue Range | Analysts |
|---|---|---|---|---|---|
| 2026 | $-0.50 | $-0.62 – $-0.39 | $381.84M | $329.55M – $407.21M | 7 |
| 2027 | $-0.22 | $-0.29 – $-0.17 | $546.27M | $484.03M – $582.38M | 6 |
| 2028 | $0.01 | $-0.11 – $0.19 | $735.77M | $706.17M – $765.37M | 6 |
| 2029 | $0.10 | $0.08 – $0.13 | $786.24M | $646.8M – $908.85M | 4 |
| 2030 | $0.22 | $0.17 – $0.27 | $872.07M | $717.4M – $1.01B | 2 |
